E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome

Clinical trial pipeline · Data from ClinicalTrials.gov

See which E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT06538181

Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

VEXAS (vacuoles, E1 ubiqutin-activating enzyme, X-linked, autoinflammatory, somatic syndrome) is a recently described disorder with severe hematologic and rheum…

United States15 participantsStarted 2025-02-13

Treatment: Pacritinib

E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

All recent trials (1 shown)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

All recent trials (1 shown)